Core Insights - Rippling, an HR software startup, raised $450 million in Series G funding, achieving a valuation of $16.8 billion, focusing on global revenue growth over immediate profitability [1][4][5] Funding and Valuation - The funding round included participation from notable investors such as Y Combinator, Elad Gil, Sands Capital, GIC, and Goldman Sachs Growth [2] - The new valuation of $16.8 billion marks an increase from the previous valuation of $13.5 billion in early 2024 [4] Employee Equity and IPO Plans - Rippling plans to repurchase up to $200 million of equity from current and former employees through a tender offer, which may become an annual event [2][3] - The CEO stated that the company does not have immediate plans for an IPO, emphasizing the need for profitability before considering going public [4][6] Business Performance and Strategy - Rippling has surpassed $100 million in annual recurring revenue and serves over 20,000 customers with a suite of more than 20 products [5] - The company is prioritizing growth over profitability, indicating a strategic choice to expand rapidly rather than slow down for immediate profit [6] Legal Challenges - Rippling is involved in ongoing legal disputes with competitor Deel, including allegations of corporate espionage, which have raised questions about competitive practices in the tech industry [7][8]

Subscribers get to use a 50+ stock model account, in-depth cash flow analyses of E&P firms, and live chat discussion of the sector. Sign up today for your two-week free trial and get a new lease on oil & gas! Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential. ...

Toyota tender offer for Toyota Industries closes, results due Tuesday | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv A man walks past the Toyota logo during a launch event in Mumbai, India, January 20, 2026. REUTERS/Francis Mascarenhas/File Photo Purchase Licensing Rights, opens new tab Companies TOKYO, March 23 (Reuters) - Toyota's tender offer to take supplier Toyota Industries (6201.T), opens new tabprivate at a price of 20,60 ...

Sampo plc, stock exchange release, 23 March 2026 at 8:30 am EET Sampo has received approval for its extended Group Partial Internal Model Distribution: Nasdaq Helsinki Nasdaq Stockholm Nasdaq Copenhagen London Stock Exchange FIN-FSA The principal media www.sampo.com Sampo estimates that as of 31 December 2025 the extended model would have reduced the group-level solvency capital requirement by approximately EUR 90 million. The extended PIM will be applied starting from the first quarter of 2026. SAMPO PLC I ...

EINDHOVEN, the Netherlands, March 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that it will report Full-Year 2025 Financial Results and host a webcast to provide a comprehensive business update on March 31, 2026. Presented by CEO Dave Marver, the webcast will be held at 2:00 p.m. CEST ...

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

Iran responded by escalating threats to target energy infrastructure and desalination facilities in the Gulf. Iranian Parliament speaker Mohammad Bagher Ghalibaf also said Saturday that entities that purchase American government bonds and "finance the U.S. military budget" would be considered legitimate targets, alongside military bases. Crude prices whipsawed in volatile trading earlier Monday, while Asia-Pacific markets traded lower. U.S. stock futures were little changed Sunday night with sentiment knock ...

Core Viewpoint - Questerre Energy Corporation emphasizes the importance of local natural gas development in Quebec for enhancing energy security amid evolving geopolitical and economic conditions [2]. Group 1: Company Developments - Questerre has completed a corporate reorganization, with economic rights to Quebec assets now held by Series 2 Preferred shareholders [1]. - The company is committed to developing its natural gas discovery in the Québec Utica, recognized as a significant undeveloped resource in Eastern Canada [3][4]. - Questerre is working cooperatively with the Government of Quebec to meet obligations under Bill 21, including demonstrating $11 million in liquidity for future well abandonments [2]. Group 2: Environmental Considerations - A peer-reviewed environmental study by CIRAIG highlights the significant environmental benefits of local gas development [2]. - The Government of Quebec's Strategic Environmental Assessment indicates that net environmental impacts from local gas development are manageable [2]. Group 3: Strategic Goals - The company aims to balance economic, environmental, and societal factors in the energy industry, advocating for public involvement in energy decisions [5]. - Questerre believes that the future of the energy industry relies on clean technologies and innovation to responsibly produce and utilize energy [4].

Core Insights - Basilea Pharmaceutica Ltd has initiated the first-in-human phase 1 study of BAL2420, a novel LptA inhibitor targeting severe bacterial infections [1][3] Company Overview - Basilea is a commercial-stage biopharmaceutical company founded in 2000, headquartered in Switzerland, focused on developing innovative drugs for severe bacterial and fungal infections [5] - The company has successfully launched two hospital brands: Cresemba for invasive fungal infections and Zevtera for bacterial infections [5] Product Development - BAL2420 is a novel antibiotic targeting LptA, crucial for Gram-negative bacteria, showing potent bactericidal activity against resistant strains like E. coli and K. pneumoniae [2] - The phase 1 study is a single-center, randomized, dose-escalation, double-blind, and placebo-controlled trial assessing intravenous administration of BAL2420 [3] - The study aims to evaluate the safety, tolerability, and pharmacokinetics of BAL2420, with data expected to support further clinical development [3] Industry Context - The CDC and WHO have identified Enterobacteriaceae, including carbapenem-resistant strains, as high-priority pathogens, highlighting the urgent need for new antibiotic treatments [2] - The development of BAL2420 has been supported by CARB-X since 2020, advancing from the Hit-to-Lead stage to the first-in-human study [4]

Core Insights - Novartis will present over 20 abstracts from its immunology portfolio at the American Academy of Dermatology (AAD) Annual Meeting, showcasing advancements in treatments for chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) [1][2][3] Immunology Portfolio Highlights - New data on Rhapsido (remibrutinib) will be presented, focusing on early symptom improvement in CSU patients, with significant changes in daily itch and hives severity scores observed as early as week 1 [2][4] - Long-term efficacy data for Cosentyx (secukinumab) will be shared, reinforcing its continuous use in HS and psoriasis, including a matched adjusted indirect comparison of its safety and flare prevention against bimekizumab [4][5] Key Abstracts - Notable abstracts include: - "Early symptom improvement with remibrutinib in chronic spontaneous urticaria" (Abstract 71668) [3] - "Flare prevention and safety of secukinumab vs bimekizumab in hidradenitis suppurativa" (Abstract 76852) [5] - "Effectiveness of Secukinumab in Preventing Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis" (Abstract 73859) [5] Commitment to Innovation - Novartis emphasizes its dedication to advancing science in immunology, aiming to provide relief for patients with autoimmune diseases through a robust pipeline and innovative treatments [6]